COO, US2166481027

The Cooper Companies sets cautious 2026 guidance, shares trade steadily on Nasdaq

Published on 06/22/2026 at 18:37 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS

The Cooper Companies updated its fiscal 2026 earnings and revenue guidance after its June quarter, while analyst estimates on the Nasdaq-listed medtech group remain closely aligned with management’s outlook.

COO, US2166481027, Illustration mit AI erstellt.
COO, US2166481027, Illustration mit AI erstellt.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 18:36.

The Cooper Companies (US2166481027) delivered updated guidance for fiscal 2026 alongside its June-quarter figures, with the Nasdaq-listed group setting earnings and revenue targets closely in line with current analyst expectations, according to recent earnings summaries and consensus data.

What the latest guidance shows

For fiscal 2026, The Cooper Companies guided for earnings per share in a corridor around 4.58 to 4.66 dollars and revenue of roughly 4.3 billion dollars, based on company and market data providers summarizing its June 4 earnings release.

In the second quarter of fiscal 2026, the company reported earnings per share of 1.21 dollars, topping consensus expectations of 1.10 dollars by 0.11 dollars, as compiled by MarketBeat from Nasdaq reporting.

Analyst consensus and Nasdaq anchor

Analyst consensus collected by MarketBeat places the current-year earnings estimate near the midpoint of management’s 4.58 to 4.66 dollar range, while revenue expectations of about 4.3 billion dollars align with the updated company guidance.

The Cooper Companies trades on the Nasdaq in the medical devices and supplies segment, where it competes with peers such as Alcon and Bausch + Lomb, and its guidance is tracked closely by US-focused medtech analysts.

Go deeper

All news and analysis on The Cooper Companies shares

Key figures, guidance updates and market data on The Cooper Companies shares are summarized in the dedicated topic area and on the company’s investor relations pages.

The products behind the guidance

The Cooper Companies generates the majority of its revenue from CooperVision contact lenses, including its Biofinity family of silicone hydrogel lenses, complemented by fertility and women’s health products in its CooperSurgical unit, according to company descriptions and recent filings.

Where the shares trade today

The Cooper Companies shares (US2166481027) trade on the Nasdaq at 65.59 dollars as of 2026-06-22, 12:08 Eastern Time, based on MarketBeat price data.

Key data on The Cooper Companies shares

  • Company: The Cooper Companies, Inc.
  • ISIN: US2166481027
  • WKN: 859395
  • Ticker: COO
  • Trading venue: Nasdaq
  • Price (as of 2026-06-22, 12:08): 65.59 USD
  • Market cap: 6.60 billion USD (as of 2026-06-22)
  • Sector / industry: Health care, medical devices and supplies
  • Index membership: S&P 500
  • Next earnings date: not officially scheduled

More on The Cooper Companies shares in social media

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities.

Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.

en | US2166481027 | COO | boerse | 69604768 | bgmi